• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603139.SS
Share

Shaanxi Kanghui Pharmaceutical Co., Ltd. Stocks

CN¥ 37.61Last Updated 18.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 582.69M

CN¥ 37.61
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shaanxi Kanghui Pharmaceutical Co., Ltd. is a Chinese company dedicated to the development, production, and distribution of a wide array of pharmaceutical products. Its comprehensive portfolio includes medications targeting numerous therapeutic areas, such as women's health, orthopedic conditions, dermatological issues, diabetes, respiratory ailments, urinary system disorders, cardiovascular and cerebrovascular diseases, gastrointestinal problems, and hepatobiliary complaints. These drugs are available in various dosage forms, including tablets, capsules, granules, mixtures, teas, plasters, ointments, liniments, lotions, and tinctures. The company's headquarters are situated in Xianyang, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.09.2026 14:03

Facebook and Instagram experienced an outage in the U.S.

21.09.2026 13:41

Poland Has Emerged From a 19-Year Stagnation: What Is Driving the Growth of Its Economy and Market

21.09.2026 13:15

"Zero Risk," Sanctions, and AI: Highlights from Revolut CEO's Interview with the Financial Times

21.09.2026 12:46

Brent crude is heading for its longest losing streak since June

21.09.2026 11:46

Google's AI has joined the "hackers' club": Gemini hacked into the systems of three companies

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026